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ABSTRACT
Pediatric anxiety disorders characterized as Generalized, Separation, and Social Anxiety
Disorders, are chronic debilitating conditions that leave children feeling tense and isolated, both
physically and emotionally. Selective serotonin reuptake inhibitors (SSRIs) are a classification
of antidepressants that can be prescribed to children diagnosed with these disorders. SSRIs have
been shown to be effective in treating anxiety disorders in children. The purpose of this literature
review was to examine and determine if there are more risks or benefits associated with SSRIs,
as well as evaluate teaching and education regarding anxiety disorder medication compliance in
both children and parents. A secondary purpose of this research was to provide recommendations
in nursing practice to allow children to feel more involved in their medical regimen. The
following databases were used for the search: CINAHL, Academic Search Premier, and Web of
Science. Key terms used in the search include but are not limited to: child* and anxiety, not
autism, and selective serotonin reuptake inhibitors, OR SSRI*, OR adolsecen*, not med*,
pediatric*, OR side effects. The results suggest that the benefits of SSRI therapy in children with
anxiety disorder, when taken on a regularly scheduled basis, outweigh the risks, however more
research aimed at compliance with SSRI therapy in children and parents is necessary. Further
research analyzing children with anxiety disorders is needed to assess SSRI usage based
specifically on their developmental age, and the inclusion of appropriate teaching and
explanation related to their diagnoses to identifying stressors that can include behavioral therapy
as well.
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INTRODUCTION

Anxiety disorders, including Generalized Anxiety Disorder (GAD), Panic Disorder, and
Social Phobia are the most common reasons children seek psychiatric medical attention and are
the most common mental health specialty for outpatient treatment. Separation anxiety and social
phobia are the most often diagnosed anxiety disorders in the pediatric population. Children
frequently suffer from anxiety in their lives, which can impair family, social, academic,
behavioral, and emotional functioning. Anxiety is defined as “apprehension, tension, or
uneasiness from anticipation of danger” (Vollmer, 2003, p. 27). The anxiety disorders are
chronic debilitating conditions that leave children feeling anxious, tense, and fearful.
Pharmacotherapy can be an effective means to treat and reduce symptoms of anxiety disorders in
children. The American Academy of Child and Adolescent Psychiatry, support the use of SSRIs
in the treatment of childhood anxiety disorders.
Current treatment guidelines for anxiety in children recommend that first line treatment
for children with generalized anxiety disorders should consist of an antidepressant therapy with
selective serotonin reuptake inhibitors or SSRIs or selective serotonin norepinephrine inhibitors
or SNRIs (Katzman, 2009). An SSRI is an antidepressant that works to block the reuptake of the
neurotransmitter serotonin in the brain. Serotonin is a neurotransmitter that plays a role in mood,
happiness, and anxiety. Two opposing theories explain the role of serotonin dysfunction:
serotonin excess where serotonin is anxiogenic and serotonin deficit where serotonin is
anxiolytic (Katzman, 2009). In a randomized control trial that was conducted, seven placebo1

controlled trials demonstrated SSRIs to be more effective than pill placebo for pediatric anxiety
disorders (Sakolsky & Birmanher, 2008).
Side effects of SSRIs include gastric upset, insomnia, and headache. Other severe side
effects include serotonin syndrome and increased risk of bleeding (Sakolsky & Birmanher,
2008). Adverse effects of SSRIs that have been reported in children include increased bleeding
and serotonin syndrome (Hammerness, Vivas, & Geller, 2006). The use of an SSRI with an
NSAID as well as the combination of an SSRI and a low-dose aspirin increases the risk of upper
GI bleeding (Dalton, Johansen, Mellemkjoer, Norgard, Sorensen, & Olsen, 2003). Side effects
and adverse reactions can provoke increased anxiety in children thus adequate education and
teaching about medication usage to parents and children can be extremely beneficial. This can be
accomplished by using techniques that are specific to the child so they can feel more involved in
their diagnosis.
Health care providers and nurses should be forewarned of the adverse effects and the
reported cases of children experiencing those effects. Nurses should be encouraged to provide
sufficient teaching to children and parents regarding medications. Educating the parents and
children of the symptoms, treatments, risks, as well as the consequences of not seeking treatment
is essential .The FDA has warned clinicians when prescribing antidepressant medications to
monitor adolescents for agitation, depression, and suicidality. Out of 100 children, one to three
will show suicidal behavior. The FDA guidelines also recommend that children and adolescents
starting treatment with an antidepressant be seen every week for the first 4 weeks, every other
week for the next 4 weeks, and then again at 12 weeks (Sakolsky & Birmaher, 2008). With this
said, clinicians, parents, children, and other health care providers should be taught the risks and
2

benefits of SSRIs. Long-term use of SSRIs in children regarding the risks and benefits have not
been studied (n.a., 2010).
Health care providers play a pivotal role in treating and providing education and teaching
to children and parents regarding medication use for anxiety disorders. In the healthcare setting,
nurses are often the first to perform an assessment and the last ones to provide discharge
instructions and education to individuals and their family members. It is crucial to have nurses
involved in education and teaching SSRI use in pediatric anxiety disorders, with emphasis on the
specific side effects and adverse effects related to the medications use.
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BACKGROUND

Anxiety disorders have an occurrence rate varying from 6% to 20% (Sakolsky &
Birmaher, 2008). Older studies suggest that 15-23% of children have some type of anxiety
disorder (Vollmer, 2003). Several studies reveal that girls far more frequently are diagnosed with
an anxiety disorder than boys (Sakolsky & Birmanher, 2008). The more prevalent anxiety
disorders are important to consider when discussing rates and commonalities. Children with
separation anxiety disorder experience a great deal of distress when separated from home or a
caregiver. On the other hand, children with generalized anxiety disorder have a constant worry
about situations and events. Children with generalized anxiety disorder experience a constant
worry about schoolwork, social interactions, world events, and family (Connolly & Bernstein,
2007). Lastly, children with social anxiety disorder have a persistent distress regarding social
situations because they fear embarrassment (Sakolsky & Birmanher, 2008). Children with social
anxiety have a constant fear of being embarrassed in social settings such as classrooms,
restaurants, and extracurricular activities (Connolly & Bernstein, 2007). Separation anxiety
disorder and specific phobia are more common in children 6-9 years of age, while generalized
anxiety disorder is more widespread in adolescence and middle childhood (Vollmer, 2003).
The symptoms of anxiety disorders greatly differ and can often be distinguished by
specific characteristics from child to child. Symptoms of separation anxiety disorder include but
are not limited to repeated nightmares of being separated, fear of being away from home or
caretaker, and repeated symptoms of headaches, nausea, and vomiting when separated. On the
contrary, symptoms of children with generalized anxiety disorder include constant worry
4

associated with symptoms such as restlessness, disturbance in sleep patterns, and irritability.
Symptoms of social anxiety disorder consist of excessive fear and avoidance of situation that is
feared (Volmer, 2003).
SSRIs are commonly well-tolerated for children and adolescents with anxiety disorders
(Sakolsky & Birmaher, 2008). SSRIs are treatment tools for anxiety disorders for children
however the risks and benefits of SSRIs should be carefully looked upon child to child
(Southammaksane & Schmitz, 2015). Examples of some SSRIs that have been reviewed as firstline treatment include escitalopram, paroxetine, and sertraline (n.a., 2010). Children with anxiety
oftentimes have parents with anxiety disorders as well thus, parents seeking their own medical
treatment regarding anxiety disorders will increase the likelihood of a child responding to
treatment (Sakolsky & Birmaher, 2008).

5

PROBLEM
Children and their parents oftentimes are not compliant with medications and therefore
do not experience the full desired effect. One area of concern that leaves parents flustered is the
duration of medication treatment, specifically medication side effects (Leonard, 2007). Side
effects are not often severe, however serotonin syndrome and serotonin withdrawal have been
reported and are more significant cases of adverse effects. Currently there is not an extensive
amount of research specifically focusing on knowledge of SSRI usage in children and parents.
However, multiple studies have shown the use of SSRIs effectiveness in the treatment of anxiety
disorders. SSRIs have been shown to be well tolerated and thus generally prescribed as first-line
treatment of anxiety disorders in children (Baldwin, Anderson, Nutt, Bandelow, Bond,
Davidson, Boer, Fineberg, Knapp, Scott, & Wittchen, 2005). Therefore education and teaching
aimed at children and parents regarding side effects in relation to compliance with medication
treatment need to be explored more in depth.

6

PURPOSE
The purpose of this literature review was to examine the risks and benefits associated
with SSRIs to determine if there are more risks or benefits with SSRI usage and evaluate
teaching and education regarding anxiety disorder medication compliance in both children and
parents. A secondary purpose of this research is to provide nursing recommendations for
children that can allow them to feel more involved and comfortable in their treatment regimen.

7

METHODS
A literature review was conducted using the following databases: (CINAHL) Plus with
Full text, Medline-EbscoHost, Google Scholar, PsycINFO, Academic Search Premier, and Web
of Science. Key search terms included, child* and anxiety, not autism, and selective serotonin
reuptake inhibitors, OR SSRI*, OR adolescen*. Other search terms used include anxiety disorder
in child* and adol*, not med*, teach* or educate*, and treatment*, education OR teaching OR
counseling, pediatric*, OR adverse, OR side effects, OR drug effects, OR effective. The results
were limited to the past ten years with an exception to classic references related to the diagnosis
and treatment of anxiety disorder in children. The exceptions included population-based cohort
studies and research articles specifically focused on the adverse effects associated with SSRIs.
Additional inclusion criteria included articles written in the English language and randomized
controlled trails. The literature will be reviewed according to side effects and child/parent
compliance on medication teaching.
A total of 266 articles were potentially related articles after searching through databases.
A total of 75 articles were found related to the topic. This number was narrowed to 40
quantitative and qualitative articles for this review. Of this, 17 articles were quantitative and 23
articles were qualitative. The articles reviewed focused on SSRI and antidepressant therapy in
children, as well as adherence and compliance of difficult treatment regimens. Review of current
evidence and research regarding childhood anxiety disorders and the risks and benefits of SSRIs
yielded towards the benefits far outweighing the risks. Originally hundreds of articles appeared
in the search and articles were excluded due to duplication within the search results and reference
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lists. Further articles were excluded due to lack of relevance of subject matter. To ensure studies
met research criteria, articles of most interest were on childhood anxiety disorders and
compliance on SSRI drug therapy. Citations from each article were analyzed and articles that
pertained to the topic were used for analysis. The extracted data was compiled into tables that
synthesize the relationship between the risks and benefits of SSRIs and compliance with difficult
treatment regimen. Further information and articles regarding nursing recommendations in
allowing children to feel more involved in their treatment was placed into a table format based
on the obtained data.
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RESULTS
Anxiety disorders are very common in the pediatric population and leave children tense
and fearful. Pharmacotherapy and adequate medication teaching to parents and children can
provide beneficial effects to children such as further changing their perspective regarding their
disorder in a positive manner. Allowing the child to feel involved in their care can lead to less
anxiety for them as well as their parents. Since SSRIs are the first line of treatment for pediatric
anxiety disorders there lies risks and benefits of the usage of them. There are extensive amounts
of research regarding the risks and benefits of SSRIs. However, there is less research on
compliance with drug therapy used in children with anxiety disorders. The following research
has been pulled from various databases to determine if there are more benefits or risks associated
with SSRIs and compliance with drug therapy used in children with anxiety disorders.
A multimodal approach is used commonly in treating anxiety disorders as this method
incorporates pharmacotherapy and education to both parents and children, behavioral therapy,
family therapy, and school personnel to just name a few. An important aspect to assess for when
looking at children is the history of onset and development of anxiety symptoms as well as their
medical and social history (Vollmer, 2003). Nurses are the first ones to perform an assessment on
a child and should therefore be aware of signs and symptoms of anxiety disorders.
The benefits of SSRIs
SSRIs have been the choice of medication for anxiety disorders in children and have been
well tolerated (n.a., 2007). It has been suggested that SSRIs are effective for treatment in
generalized anxiety disorders, separation anxiety disorders, and/or social phobia in children and
10

adolescents (da Costa, Morais, Zaneta, Turkiewicz, Neto, Morikawa, Rodrigues, Labbadia, &
Asbahr, 2013). SSRIs are the most commonly prescribed antidepressants for anxiety disorders
because of their favorable side effects and the benefit of treating co-morbid depression (Hoffman
& Mathew, 2008).
It is important to treat anxiety disorders as early as possible as delaying treatment can
lead to mood disorders in late adolescence into adulthood (Wehry & Strawn, 2014). The
strongest evidence suggests the use of SSRIs and emphasizes the importance of starting
treatment early to prevent problems in adulthood. A child with anxiety disorders places them at
risk for later anxiety disorders, mood disorders, substance abuse disorders, and uncontrollable
behavior if not treated early (Mohatt, Bennett, & Walkup, 2014). SSRIs require less initial
medical evaluation, medical monitoring while on the medication, and have fewer side effects
(Keeton, Kolos, & Walkup, 2009). They have mostly replaced tricyclic antidepressants because
of the safety concerns and monitoring of cardiovascular effects that were associated with
tricyclic antidepressants (Leonard, 2007). SSRIs have replaced benzodiazepines as well
(Allgulander, Florea, Huusom, 2006). Some types of SSRIs that are currently being used in the
United States include escitalopram, fluoxetine, paroxetine, and sertraline.
Sertraline which was studied in the Child/Adolescent Anxiety Multimodal Study
(CAMS) with a pill placebo, sertraline alone, Cognitive-Behavioral Therapy (CBT), and the
combination of CBT and sertraline showed that it was well tolerated and there were no
significant adverse effects noted. Fluvoxamine was studied by the Research Unit on Pediatric
Psychopharmacology Anxiety Study Group in a double-blind placebo-controlled trial which
suggested that adverse effects and side effects such as abdominal pain and behavioral
11

disinhibition were minimal (Mohatt, et. al.). There are several variables that should be considered
when starting an SSRI treatment that can potentially reduce the risks of the antidepressant. Those
variables include the child’s age, weight, neurologic status, and family history. Side effects are
reported but are usually mild and are often dependent on the dose taken. Cerebrovascular adverse
reactions have very low rates when compared to SSRIs (Hammerness, Vivas, Geller, 2006). It is
important to note that adverse reactions and side effects can occur but the likelihood of them
occurring with an SSRI is low. According to the FDA (2005), no completed suicides have been
attributable to the use of SSRIs in children.
Although the risk of suicidal ideation is discussed with SSRIs, the benefits seem to
outweigh the risks (Southammakosane & Schmitz, 2015). According to March and Vitiello
(2009) there has not been any completed suicide among 4,000 participants of the study that were
treated in randomized clinical trials. The way an SSRI is prescribed regarding dosage is crucial
when considering the potential risks and benefits. Titration should be used because this could
also increase the benefits of the medication. Dosages should be started off low and gradually
increased until symptoms are relieved. It is important to note that children may experience
somatic symptoms prior to treatment but more importantly this decreases with treatment. In a
systematic review and meta-analysis of prospective randomized parallel-group controlled trails,
nine trials of 1,673 participants and six medications demonstrated efficacy and no increased risk
was observed for nausea/abdominal symptoms, discontinuation as a result of an adverse reaction,
or suicidality. The results of the study suggests that SSRIs/SNRIs are superior relative to placebo
(Strawn, Welge, Wehry, Keeshin, & Rynn, 2015).
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First-line agents such as SSRIs have been studied numerous times in double-blinded
studies and placebo-controlled trials in adults and children (n.a., 2010). For example in a
multicenter randomized double-blind, placebo-controlled trial that was conducted, paroxetine
greatly increased the number of responders compared to a placebo. The study concluded that
paroxetine produces few severe side effects and is the choice of medication for children with
social anxiety disorder (Manassis, 2005). Fluoxetine is also recommended as the first choice of
medication for children and adolescence with anxiety disorders. According to the FDA, two
SSRIs have been approved for children with anxiety disorders: escitalopram and fluoxetine
(Rappaport, Kulick, & Phelps, 2013). Fluoxetine has an advantage over other SSRIs because of
its long half-life (Kitts & Goldman, 2012).
A number of randomized controlled trials conducted between 1988 and 2006 concluded
that the benefits of antidepressants outweighed the risks to children with anxiety disorders
(Rappaport, et. al.). It is recommended that a child stay on antidepressants for at least a year so
they can experience a full cycle of usual situations that provoke anxiety. It is advised not to
discontinue the medication especially during stressful events in a child’s life (n.a., 2010).
Following the prescribed regimen can greatly increase the benefits of taking the medication.
Even though practitioners need to be aware of the possibility of suicide in children whom
they are prescribing SSRIs, concerns of this are outweighed by the positive effects of the
medication. The positive effects include a decrease in the burden of the disorder and reduction in
symptoms (Southammakosane & Schmitz, 2015). In a double-blind, randomized, placebo
controlled trial, escitalopram was well tolerated and there was no evidence of increased suicide
in this group when compared to the placebo group (Isolan, Pheula, Salum, Oswald, Rohde, &
13

Manfro, 2007). Based on randomized placebo-controlled trials conducted on fluoxetine,
fluvoxamine, paroxetine, and sertraline the results indicated that antidepressants appear to be the
greatest benefit for pediatric anxiety disorders. In a randomized, placebo-controlled trial that
studied the effect of venlafaxine to an SSRI, venlafaxine showed to have more adverse effects
such as an increase in blood pressure and heart rate (Sakolsky & Birmaher, 2008).
The Child/Adolescent Anxiety Multimodal Study (CAMS) was the largest randomized
controlled, multi-site comparative trial conducted on cognitive-behavioral therapy (CBT),
sertraline, their combination, and a placebo in children diagnosed with separation, generalized,
and social anxiety disorders (Piacentini, Bennett, Compton, Kendall, Birmaher, Albano, March,
Sherrill, Sakolsky, Ginsburg, Rynn, Bergman, Gosch, Waslick, Iyengar, McCracken, & Walkup,
2014). The study included evaluations of which included assessments of adverse reactions,
harm-related adverse reactions, physical symptoms, adherence of medication, and lastly clinical
improvement. These particular assessments were used to gather more information from the child
and families and also clinicians themselves. This study leads to the importance of frequently
monitoring baseline physical and psychiatric symptoms, adverse reactions, and adjusting
medication treatment according to symptoms (Rynn, Walkup, Compton, Sakolsky, Sherrill,
Shen, Kendall, McCracken, Albano, Piacentini, Riddle, Keeton, Waslick, Chrisman, Iyengar,
March, & Birmaher, 2015). The results of this study suggest that response to both CBT and
SSRIs are efficacious and were associated with minimal adverse effects (Piacentini, et. al.).
An open-label trail conducted on children and adolescents with social anxiety disorder
included sertraline, citalopram combined with psychoeducation interventions, and a randomized,
16-week, double-blind, placebo-controlled trial with paroxetine suggested that SSRIs are an
14

effective choice of medication for anxiety disorders. In the open-label trail of escitalopram on
children and adolescents with social anxiety disorder, the study demonstrated no significant
changes in weight or vital signs. Also no participant developed self-harm behavior or suicidal
ideation (Isolan, et. al.).
The risks of SSRIs
Prescribing medications can be difficult when it comes to outweighing the risks and
benefits especially in the case for children. Parents are reluctant to give medication to their
children when side effects and risks of suicide are involved. Prescribing rates of SSRIs have
increased despite the concerns of potential adverse events (March & Vitiello, 2009). Although
the risk of suicidal behavior is low, the fact that it is consistently brought up in a number of
studies raises a concern (Wohlfarth, Zwieten, Lekkerkerker, Gispen-de Wied, Ruis, Elferink, &
Storosum, 2006). All SSRIs are known to have similar mechanisms in their action, however they
differ in chemical structure and the way they are metabolized, absorbed, excreted, and distributed
in the body. Another area to consider is how children are continuously changing physiologically
thus altering the way a drug is metabolized and its adverse effects (Czaja, Valuck, & Anderson,
2013).
Suicide is the third leading cause of death in individuals from the age of 10 to 19, making
it a serious health concern. Suicidal thoughts and behaviors are the most troublesome for
children, families, and clinicians (Rynn, et. al.). Although the risk of suicide is low, it is still an
important health issue because of the widespread use of SSRIs in the country (Fergusson,
Doucette, Glass, Shapiro, Healy, Hebert, & Hutton, 2005). Increased risk of suicide, depression,
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and development of other anxiety disorders has been linked with social anxiety disorder in
adolescents (Isolan, et. al.). There is an increased risk of suicidal ideation as well as suicide
attempts in children who are prescribed antidepressants when compared to placebo (Leonard,
2007). The UK Department of Health alerted the public of a 1.5-3.0 fold increased risk of
suicidal ideation and harm to self in children taking paroxetine (Hammerness, et. al.). The 9-year
cohort study that was conducted from British Columbia on antidepressants and the association of
an increased risk of suicidality in children, supports the decision of the FDA to include the black
box warning on all antidepressants regarding potential risk of increased suicidal behavior in
children and adolescents (Schneeweiss, Patrick, Soloman, Dormuth, Miller, Mehta, Lee, &
Wang, 2010). The FDA also recommends weekly appointments with the child for the first 4
weeks and then going to every other week for 4 weeks (Rynn, Puliafico, Heleniak, Rikhi, Ghalib,
Vidair, 2011).
The FDA provides the public with safety measures which include medication guides that
uses a practical, reader-friendly approach to address the risk of suicidality (Barry & Busch,
2010). Because of the black box warning issued back in 2004, clinicians have decreased the
number of antidepressants prescribed to children and adolescents in Nebraska which is consistent
with the decrease in the national average. Continuing education and increasing comfort levels is
important for both the child and clinician as a fair amount of children and families have refused
their medications after the black box warning (Bhatia, Rezac, Vitiello, Sitorius, Buehler, &
Kratochvil, 2008).
Other adverse effects may be seen with SSRIs. Adverse effects such as serotonin
syndrome have been reported in children taking these antidepressants. Reported cases of
16

extrapyramidal symptoms, tics, and myoclonus have been documented in children taking SSRIs
(Hammerness, et. al.). Other adverse effects include nausea, sweating, sexual dysfunction, etc.
(n.a, 2010). Some common side effects include headache, insomnia, GI upset, etc. Children
taking these antidepressants should be monitored for sleep problems, irritability, increased
thoughts of suicide, and akathisia (Sakolsky & Birmaher, 2008). The two most common
categories of adverse effects are physical (headaches, GI problems) and psychiatric symptoms
(agitation, suicidal ideation) (Strawn, et. al.).
Another issue with SSRIs is that abrupt discontinuation can lead to withdrawal symptoms
(Katzman, 2009). Abrupt discontinuation can cause children to experience dizziness, nausea,
headache, and fatigue (Southammakosane & Schmitz, 2015). A Cochrane review of 15 SSRI
pediatric anxiety clinical trials found that the children and adolescents experienced increased
irritability, hostility, insomnia, and restlessness as compared to the pill placebo and that these
adverse reactions often lead to discontinuation (Rynn, et. al.).
Therefore health care providers should try to avoid this by reducing the dosage of the
medication over time. In a randomized double-blinded study that was conducted, the most
common adverse reactions after giving paroxetine were insomnia, decreased appetite, and
vomiting. Five out of the hundred twenty-five responder’s experienced suicidal thoughts or selfharmed compared to non in the placebo (Manassis, 2005). Even though the numbers stand small,
they still contribute to the whole and because of these effects parents worry about giving their
children SSRIs.
Side effects of SSRIs should be particularly monitored during the first 10 to 42 days of
treatment (Lovrin, 2009). SSRIs increase the risk of upper GI bleeding and this can also occur
17

with the concurrent use of an NSAID (Dalton, Johansen, Mellemkjoer, Norgard, Sorensen, &
Olsen, 2003). Some serious side effects of SSRIs are mania, seizures, hyponatremia, and
arrhythmias. Less serious side effects include dry mouth, sweating, diarrhea, etc. (Rappaport, et.
al.). Headaches, stomach aches, and behavioral problems can arise frequently when taking SSRIs
and should be looked upon specifically. The CAMS study revealed that children and adolescents
experienced difficulty sleeping more often than when compared to the pill placebo. The study
also revealed that children reported more frequent headaches than compared to the pill placebo
and that children showed more symptoms of psychiatric adverse reactions (Rynn, et. al.). SSRIs
can also slow growth causing a decrease in growth hormone levels so therefore it is extremely
important to monitor the child’s height, weight, and physical status. Other serious adverse
reactions that need to be aware of include behavioral activation and mania (Keeton, et. al.).
The half-life of a drug also influences the risk of adverse effects. Children and parents
should be cautioned about this and how missing doses can cause harm. Fluoxetine with the
longest medication half-life reveals a smaller risk of suicidal ideation when compared to
venlafaxine and fluvoxamine, which are medications that have shorter half-lives (Smith, 2009).
In August 2011, the FDA also released a caution to the public about an increased risk of cardiac
adverse reactions with higher doses of citalopram. With this said, citalopram has not been
approved by the FDA for use in children under the age of 18 even though it is still prescribed in
the pediatric population (Czaja, et. al.).
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Parent-child compliance on treatment regimen
Parents can become sensitive when it comes to their child’s diagnosis and prescribed
medications. Many questions arise such as side effects, adverse effects, duration of treatment, or
other possible treatments. Generally speaking it is important to start off on low dosages of SSRIs
and concurrently review the side effects, treatment response, and adjusting dosages/treatment as
needed (Keetonm, et. al.). It is imperative to help parents understand their child’s stressors and
sadness because this can typically strengthen the ability to support their child and possibly
reduce anxiety and depression in the future. Some protective factors that can help reduce a
child’s stressor(s) include self-esteem and confidence, family support, hopefulness, goal-directed
thinking, and positive family relationship (Kitts & Goldman, 2012). This is where determining
the risks and benefits come into play when prescribing an SSRI to a child since parents prefer
treatments when the benefits outweigh the risks. SSRIs should be used in the treatment plan of
pediatric anxiety disorders as well as family education specifically focusing on the side effects of
drugs (Lovrin, 2009).
Some common reasons that a family may need to consult with a mental health clinician
include questions regarding a diagnosis, safety concerns such as suicidal ideation, and concerns
regarding adverse reactions of the medication (Kitts & Goldman, 2012). Nurses and practitioners
need to be aware of explaining the risks and benefits of each treatment to families before they are
faced to make a decision. Children and their parents should be told what to expect after taking
the medication, the side effects, what to do when the effects occur, and how the health care
provider will manage that if those problems arise (Rynn, Puliafico, Heleniak, Rikhi, Ghalib, &
Vidair, 2011). The clinician needs to portray the information of the risks vs. benefits to the parent
19

and child (Strawn, et. al.). Practitioners should obtain accurate baseline measurement of physical
symptoms and track these symptoms overtime (Rynn, et. al.). An area of concern to parents is the
duration of treatment and how often side effects are experienced (Leonard, 2007). Another area
of concern to parents is not feeling active enough in their child’s treatment process. A challenge
that arises is the limited insight and communication that children have which leads them to less
likely seek help from their health care provider (Kitts & Goldman, 2012). However, assuring
them that they are an active part of the treatment and that everything will be discussed with them
usually resolves their concerns (Rappaport, et. al.).
Psychoeducational psychotherapy should contain the following components: education,
support, and skill building. This will allow families to become better involved in the medication
treatment. The goal of this type of therapy is to teach families about the medications, strategies to
follow the medication regimen, how to communicate with their prescriber, and manage side
effects (Cummings & Fristad, 2007). More positive studies done have shown that when a parent
is involved in a child’s medical care, there is an increase in response to the child’s treatment
compared to when a parent does not have an added benefit (Lebowitz, Woolston, BarHaim,
Calcocoressi, Dauser, Warnick, Scahill, Chakir, Shechmer, Hermes, Vitulano, King, & Leckman,
2013). It is crucial to have parent’s beliefs and values discussed before treatment begins and to
offer supportive psychoeducation that encompasses safe and effective treatment options (Keeton,
et. al.). Some factors that should be discussed also include education about the drug which
should include length of time until therapeutic response is seen and any medication specific
questions (Lovrin, 2009). Other considerations include scheduling more frequent follow-up
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visits, increasing use of psychotherapy, and adding more telephone contacts between visits can
help children adhere to their treatment plan (Bhatia, et. al.).
Regardless of the type of therapy, consent should always be discussed. Consent
specifically regarding SSRIs should include the possibility of increased risk of suicidal thinking,
safety concerns, and adverse reactions (Southammososane & Schmitz, 2015). Parents that suffer
from anxiety disorders themselves are more likely to have children diagnosed with anxiety
disorders as well (Keeton, Ginsburg, Drake, Sakolsky, Kendall, Birmaher, Albana, March, Rynn,
Piacentini, & Walkup, 2013). It is important to have families communicate amongst each other to
try to reduce tension, stress, and anxiety. Family conflict can arise however, if a child’s anxiety
requires family accommodation just as family conflict can increase a child’s anxiety (Keeton, et.
al.). The likelihood that a child will respond to treatment increases when a parent seeks their
own medical help; thus it is crucial to have parents treated as well (Sakolsky & Birmaher, 2008).
Family education can reduce the re-occurrence of anxiety in children; however parents
with their own anxiety disorders should seek separate treatment as well (Mohatt, et. al.). It is also
important to take into consideration that it takes a family time to readjust their parenting to a
child that does not experience anxiety any longer (Keeton, et. al.). Sometimes contacting the
child’s school teacher or guidance counselor can help clarify the severity of the anxiety reported
by two parents or a parent and child (Kitts & Goldman, 2012). It is the responsibility of the
health care provider to provide information regarding risks vs benefits of treatment options to
children and families and help them understand which treatment modality is be best for them as
the initial choice of treatment (Rynn, et. al.).
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Besides educating the children and parents, written materials and reputable websites on
pediatric anxiety disorders can be provided so families can have a better understanding about the
disorder, treatment, and side effects (Sakolsky & Birmaher, 2008). The health care provider
should leave a detailed instruction to the families about the medication and its benefits, side
effects, potential adverse reactions, and the FDA indication of use. Parents and families should
be educated on discontinuing medications as abrupt discontinuation can lead to potential
withdrawal effects (Keeton, et. al.). The majority of guidelines and resources focus on the
education aspect to the parents directly, but forget to communicate with the child one on one.
Explaining in words so the child can understand is vital. This should involve educating the child
about his/her medical condition, the risks and benefits of the SSRI, assessing the child’s level of
understanding, and a review of the child’s willingness to accept the treatment. If however, the
child can demonstrate a full understanding of the risks and benefits of the medication and refuses
to proceed with the current treatment and the medication is not essential for him or her the
medication can be delayed to a later time (Costea, Barreto, & Burns, 2008). Educating both the
child and family impacts their way of thinking and increases motivation on addressing their
concerns regarding symptoms (Keeton, et. al.).
Another method used in educating families is called shared decision-making. This a type
of method that takes a step back and focuses on the child itself. The treatment decision is based
on the child’s beliefs and values. Some of the important characteristics that makes this a shareddecision making process include the following: the child’s outcome, beliefs, values, and
perspectives are taken seriously, the child is kept safe, and the child can make health-related
decisions regarding treatment options. This can be used along with family teaching and where
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adherence to medication is required to provide the most beneficial teaching to children and
families (Lovrin, 2009). It is often helpful to take into consideration the parent’s opinion as this
approach can address the family’s concerns/questions and strengthen the therapeutic relationship
(Kitts & Goldman, 2012). Family Talk Preventive Intervention is a type of method that can be
used also. This intervention includes five to seven sessions that focuses on positive interactions
between parents and children, increasing understanding of the illness/disorder, and increasing
ways to communicate between parents and children (Kitts & Goldman, 2012).
Given children’s developmental stage, it gets challenging to present information to them.
When attaining a child’s acceptance of treatment, taking into consideration the developmental
stage and level of understanding is necessary. For example a preschooler may not understand
information given to them so involving them in a discussion can increase trust and lead to a
better treatment response. On the other hand a school-aged child can show understanding of how
medicine works in the brain and in the body (Francis, 2008). Adolescents tend to like to be
treated with respect and dignity more which can help foster the relationship (Lovrin, 2009).
Informed assent should be the developmental process used for children so they have a better
understanding of their disorder and thus show positive outcomes (da Costea, et. al.).
The U.S. Pharmacopeoia (USP) Pediatrics Advisory Panel on Children and Medicines
(2008) conducted interviews with different health professionals and educators developing
developmentally appropriate educational guidelines for children so that they can receive the right
information and communication about medications. Prior to asking questions, it is a good first
step to engage the child in playful age appropriate language before asking anxiety or behavioral
specific questions (Keeton, et. al.). These educational guidelines include what health care
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providers believe children should know about their medications, considering what children want
to know, answering any questions or concerns children have about their medication, providing
the general risks and benefits of medications, teaching children how and when to ask questions,
and lastly having parents demonstrate the proper use of medication (Francis, 2008).
Screenings can be done as an early assessment tool to determine which children are at
greatest risk regarding their anxiety. Some of these screenings include the Multi-dimensional
Anxiety Scale for Children and the Screen for Child Anxiety Related Emotional Disorders for
anxiety symptoms (n.a., 2007). Screenings developed by other scholarly figures include a
separate parent and child version. This screening is called Screen for Child Anxiety Related
Disorders or SCARED (Birmaher, Brent, Chiappetta, Bridge, Monga, & Baugher, 1999). These
screenings can be compared to the child and parent as the child screening alone may provide
more information than the parent (Sakolsky & Birmaher, 2008). The screenings can potentially
lead to improved long-term functioning in children. However, two ethical issues stand in the way
when it comes to education in children. The first are the benefits and risks that come with taking
medications for long term use and second is the possible benefit of decreasing anxiety when
offering an explanation that takes into account hope which can be weighed against the risk of
increasing anxiety with long term use of treatment. Taking into consideration the developmental
stages and the assessment screenings of children along with more creative and thorough
discussions about their medications can potentially reduce the risks and enhance the benefits of
medication use in children (Francis, 2008).
Phelps (2013) recommends that the evaluation of a child should include the following:
interviewing the family, getting information from the child’s school and other health care
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providers, and using screening tools and/or rating scales completed by the families and possibly
teachers. The evaluation performed should include three aspects of anxiety disorders: behaviors,
thoughts, and physical symptoms. According to Keeton, et. al. (2009), the final evaluation
should include a psychiatric history, medical screening, questions from the child’s
academic/social/ emotional functioning, and family mental health history. The black box warning
should also be included in the discussion of the risks and benefits of SSRIs. Treatment should be
done as early as possible as delaying treatment can increase the child’s risk of significant life
impairment, re-occurrence of symptoms, and development of other psychiatric disorders
(Mohatt, et. al.).
Certain behaviors may strengthen therapeutic communication and increase validity of the
interview process for a child or adolescent. Some of these behaviors that the nurse or health care
provider can perform include actively listening, showing interest in the disease/disorder, starting
off with a friendly question, and making eye contact. Enhancing cooperative collaboration with
children and adolescents can be challenging but promoting this can help collect better
information from the child and reduce clinician bias. Other behaviors that can be helpful are
using developmentally appropriate language, allowing the child time to speak when asking
questions, and empathizing with the individuals. On the contrary, behaviors that should be
avoided because they can worsen therapeutic communication and reduce the effectiveness of an
interview include interviewing a child right after a procedure, entering with a large group, early
morning rounding if the child is not a morning person, and dismissive behaviors. Reasons for
treatment failure include misdiagnosis, inappropriate pharmacotherapy, cultural/ethnic factors,
and medication side effects (Kitts & Goldman, 2012).
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DISCUSSION
The benefits of SSRIs
Based on the findings from the literature review, an extensive amount of the review
supports the use of SSRIs because of the benefits outweighing the risks. One of the benefits
include significant improvement in anxiety severity in fluoxetine when compared to a placebo
(da Costa, et. al.) This is where parents feel more comfortable when their child is prescribed an
SSRI when they are explained the benefits rather than the very few risks. Other benefits include
no increased risk of nausea/abdominal symptoms, adverse reactions, or suicidality. SSRIs
showed superiority relative to placebo in many studies conducted (Strawn, et. al.). The research
suggests that SSRIs produce few to none adverse reactions and show them to be safe and well
tolerated among the pediatric population. SSRIs are the first line of treatment for anxiety
disorders and produce few side effects (Cummings & Fristad, 2007).
The risks of SSRIs
The research shows the benefits being far greater than the risks when it comes to SSRI
usage, however there lies very few risks that should be discussed and mentioned to children and
parents so they are fully aware of all the benefits and risks. Many studies showed a slight
increase in suicide risk when taking an antidepressant. However, because of the very small
number of completed suicides the benefits seem to far outweigh the risks of this. An important
note to consider is the FDA’s black box warning of the increased risk of suicide. As mentioned
previously, even though it is a small increased risk clinicians should still explain this to families
so they are forewarned. Even though side effects such as headache, insomnia, GI upset,
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irritability, increased thoughts of suicide, and akathisia can occur, they are still not significant
enough to withhold and abruptly discontinue the medication (Sakolsky & Birmaher, 2008).
Again, thorough discussion about the possible side effects and adverse reactions should be
explained to families but with the risk of them occurring to be slightly low.
Parent-child compliance on treatment regimen
As discussed throughout this literature review, having parents and children comply with
their medication regimen is very important in order to make sure children are receiving the best
and appropriate care possible. Many resources can be used in this aspect of care to help ensure
children are safe and parents are comfortable. Some of these resources include providing
families with reputable websites on their child’s diagnosis, psychotherapy, shared-decision
making, anxiety rating scales, and developmentally appropriate explanations to children. Family
education and presenting age appropriate explanations to children can further reduce tension and
anxiety (Mohatt, et. al.). Increasing therapeutic communication can also play a major role in
allowing a child to feel more involved in their diagnosis. Consent is something that is sometimes
overlooked and should be explained fully about the possible adverse reactions and safety
concerns (Southammososane & Schmitz, 2015). This can again further enhance compliance on
children taking their medication and allow parents to feel better about their child’s care. Children
should be priority and letting them feel involved in every bit of their care can only reduce
tension and make the transition for them easier.
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LIMITATIONS
There were several limitations to the review of this literature. A few of the research
articles and studies dated back prior to ten years but was still used in the literature review
because of its strong relevance to the topic. Searching for use the most up-to-date research is a
limitation since most of the articles and studies discussed range closer to 2005-2008. Also, the
main focus of this review was on the pediatric population and many of the research studies
included adolescents in the age group. These articles were still used because of the limitation of
studies primarily focusing on the pediatric population. Another limitation was the use of SNRIs
along with SSRIs in the studies. This adds more to the research but strays away from the topic of
just SSRIs.
Some studies were conducted outside of the United States such as Denmark, thus the
findings of these studies many not be generalizable to the United States acute care setting. A lack
of research lies in drug compliance with parents and children and recommendations to make in
nursing to have families and children comply with medication better. A lack of research also lies
in focusing just on the nursing aspect and what nurses as health professionals can do to better
facilitate care of children with anxiety disorders.
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NURSING IMPLICATIONS
Overall, a substantial amount of research supports the effectiveness of SSRIs in the
treatment regimen of pediatric anxiety disorders. With a small increased risk of suicide and few
side effects, SSRIs are still closely monitored. Preliminary evidence provides support to include
the risks and benefits of SSRIs in the teaching aspect of a child’s medical care. Families should
all feel involved in the care of their child with main priority and focus on the child no matter
his/her age. Developmentally appropriate care should be used as this can facilitate better
involvement and compliance for children. With this said, nurses should be aware of all the
obstacles families and children can face when diagnosed with an anxiety disorder and help
incorporate compliance, safety, and reassurance in their medical care.
Nurses as well as providers are in a position where they can educate, relieve
stress/tension, provoke safety, and provide resources to families regarding their child’s anxiety
disorder(s). It is vital to have the education be centered on each family’s needs and wants. This
can sometimes become challenging for nurses when each family is structured differently; but by
encouraging nurses to have an open mind with respect to different cultures the challenge can
further be reduced. It is important to note that sometimes health professionals forget that the
child is the center of care and focus most of the care on the family as a whole. Special
consideration and attention should be given first to the child presenting with the diagnosis. Age
appropriate words, diagrams, pictures, or videos can be given to children explaining about their
disorder. Allowing them to feel as involved in their medical care as possible can relieve and
reduce further anxiety and tension. Nurses should be encouraged to speak directly to the child
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first before speaking with the parents. Getting to know the child, his/her stressors, likes and
dislikes is important for the nurse to take away when providing care of a child with an anxiety
disorder. Permitting the nurse to have one-on-one time with the child can possibly reduce a
child’s anxiety. This is not done as often as it should be, but the focus of care should be the child
first then parents and family together.
Nurses are the eyes and ears to everything. Specifically, they are the ones to provide
discharge instructions and teaching when families are leaving the hospital. Education and
providing resources to children and families becomes very important here. Nurses should be
taught how to thoroughly give instructions to families and children regarding their disorder. This
includes the risks, benefits, side effects, adverse reactions, and dosages of all the medications
prescribed. As mentioned above, nurses might have to sometimes deliver instructions in a
different manner to parents and children. Nurses and health professionals cannot forget that the
child is the center of the medical care and should be told everything about their medications.
Nurses should provide all the relevant resources which can include reputable websites, broachers,
referrals, etc. when educating families. Specific training can be given to health professionals
which can help them provide the best and effective teaching to parents and children.
Safety is key when it comes to caring for the pediatric population. Safety is encompassed
everywhere from a child’s hospital stay to making sure they understand the risks and benefits of
taking SSRIs. Depending on the type of anxiety disorder, nurses should be alert for what can
trigger more anxiety in a child or what a child prefers or doesn’t prefer. All of these
considerations as well as many more should be incorporated in a child’s hospital stay or daily
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living. Because of the difficulty children experience when diagnosed with an anxiety disorder,
safety of all measures should be highly encouraged.
All in all, more research and studies should be conducted specifically on nurses and how
they deal with children presenting with an anxiety disorder. This can further unwrap some
information and educate nurses themselves on how to better effectively treat individuals with
anxiety disorders. Nurses should also be experts on medication teaching and letting their children
know what to expect and what not to expect when taking their medications. They should
familiarize themselves with the medications the child is prescribed, and the family altogether.
Pediatric nurses should also take continuing education on how to deal with children with anxiety,
tension, and fear on ways to communicate effectively with these children to ease their anxiety.
Providing detailed instructions, teaching, promoting safety, and providing all the resources and
care possible from pediatric nurses can leave children happy and healthy.
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RECOMMENDATIONS FOR PRACTICE
Pediatric nurses need to become experts in effective communication since it is an
essential element of caring for pediatric anxiety disorders. Nurses should get to know the child
before providing care. This can include the child’s likes/dislikes, stressors, fears, etc. Nurses
need to be encouraged to provide direct care to the child itself and allow them to feel as involved
and comfortable in their care as possible. This care should include developmentally age
appropriate teaching and explanations about their diagnosis, effective therapeutic communication
especially during times of excess anxiety or stress in the child’s life, allowing the child to ask
questions or any concerns they might have, and speaking to the family as a whole to make sure
everyone understands the purpose of treatment. The key should be to provide medical and
nursing care to the child first and making sure they are safe and comfortable before anything
else. Facilities and hospitals should devise a plan that all pediatric nurses follow when caring for
children with anxiety disorders. This plan can ensure that all staff members are educated on the
topic and provide the same level of care to individuals.
Making simple changes to the environment can also allow a child to feel safer. This may
include reducing medical equipment in the room or providing toys, books, and games for the
child to ease their tension being in an unfamiliar setting. Nurses need to also make sure they are
effectively and properly discussing what to expect and what not to expect from a child’s
medication regimen to the child and parents. It is important to have nurses speak directly first to
the child and have them understand the treatment regimen and then include the parents in the
plan. Nurses need to be through in their teaching to children and families specifically focusing on
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the risks and benefits of their medications. Additional training may need to be encouraged for
pediatric nurses specifically focusing on medication teaching and understanding the risks and
benefits of all SSRIs. This will allow nurses to be fully competent in providing education to
families.
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APPENDIX A: TABLE OF EVIDENCE
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Articles

Purpose

Method

Study
Design

Sample

Results (key
findings)

Nursing implications

Strawn, J. R., Welge, J.
A., Wehry, A. M.,
Keeshin, B., &
Rynn, M. A. (2015).
Efficacy and
tolerability of
antidepressants in
pediatric anxiety
disorders: A systematic
review and meta
analysis. Depression
and anxiety, 32(3),
149-157.

To test the
efficacy, safety,
or tolerability of
antidepressants in
pediatric anxiety
disorders.

A systematic
review and
meta-analysis
of
prospective,
randomized,
parallelgroup,
controlled
trials of
SSRIs and
SNRIs in
pediatric
patients with
nonobsessive
compulsive
disorder
(OCD) was
searched
using
PubMed/Med
line from
1966-2014.
The metaanalysis used
models such
as the
Pediatric
Anxiety
Scale to
evaluate

Systematic
review and
metaanalysis of
prospective
randomized
parallelgroup,
controlled
trials

1,673
pediatric
patients
with nonobsessive
compulsive
disorder
(OCD)
anxiety
disorders
were
sampled

Nine trials of
1,673 patients
and six
medications
demonstrated
efficacy and no
increased risk
was observed
for
nausea/abdomin
al symptoms,
discontinuation
as a result of an
adverse
reaction, or
suicidality.
SSRIs/SNRIs
suggest
superiority
relative to
placebo for the
treatment of
pediatric
anxiety
disorders.

Health care providers
as well as nurses need
to be aware of the
current medication
treatments/guidelines
that are effective or
not in treating
pediatric anxiety
disorders. This study
suggests that SSRIs
are indeed successful
in treatment.
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changes in
symptoms,
suicidality,
and adverse
effects.
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Keeton, C.P.,
Gingburg, G.S., Drake,
K.L., Sakolsky, D.
Kendall, P.C.,
Birmaher, B.,
&…Walkup, J.T.
(2013). Benefits of
child-focused anxiety
treatments for parents
and family functioning.
Depression & Anxiety
(1091-4269), 30(9),
865-872.

To examine
changes in parent
global
psychological
distress and family
dysfunction/burden
and to determine
whether or not
these changes were
in relation to
parent and family
factors associated
with the child’s
treatment
condition and
response

The 488
youths were
randomly
assigned to 12
weeks of
individual
cognitive
behavioral
therapy
(CBT),
mediation
treatment of
sertraline,
their
combination,
or medication
management
with a placebo
within the
Child/Adolesc
ent
Multimodal
Study
(CAMS). At
pre and
posttreatment
children
completed a
measure of
family

Randomized
controlled
multi-site
comparative
treatment
trial

488 youths
aged 7-17
years who
meet the
criteria on
the DSMIV-TR for
social
phobia,
separation
anxiety,
and/or
generalized
anxiety
disorder,
and their
parents

Parental
psychological
distress and trait
anxiety, and
parent-reported
family
dysfunction
improved only
for parents
whose child
were rated as
treatment
responders, and
these changes
were unrelated
to treatment
condition.
Regardless of
treatment
condition or
response,
family burden
and childreported anxiety
treatments
improved
considerably
from pre to
posttreatment.
If children

The results of these
findings can be used to
help children and
families that suffer from
anxiety to use childfocused anxiety
treatments to lessen the
severity of the anxiety
among the children and
also parents. Nurses can
educate families on the
benefits of child-focused
anxiety treatments.
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functioning
and parents
completed
measures of
trait anxiety,
psychological
distress,
family
functioning,
and burden of
child illness.

respond
successfully to
treatment,
findings suggest
that childfocused anxiety
treatments can
result in
improvements
in nontargeted
parent
symptoms and
family
functioning.
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Dalton, S. O.,
Johansen, C.,
Mellemkjær, L.,
Sørensen, H. T.,
Nørgård, B., & Olsen,
J. H. (2003). Use of
selective serotonin
reuptake inhibitors and
risk of upper
gastrointestinal tract
bleeding: a populationbased cohort
study. Archives of
Internal
Medicine, 163(1), 5964.

To examine the
risk of upper
gastrointestinal
bleeding in
patients taking
antidepressants
specifically
SSRIs.

All users of
antidepressants in
North Jutland
County, Denmark
from January 1,
1991, to December
31, 1996 were
identified using the
PharmacoEpidemiologic
Prescription
Database of North
Jutland. Among
the users taking
antidepressants,
hospitalizations for
upper GI bleeding
which was
searched from the
hospital discharge
register, was
compared with the
number of
hospitalizations
who did not have
prescriptions for
antidepressants.

PopulationBased
Cohort
Study

490,000
inhabitants of
North Jutland
County,
Denmark from
January 1,
1991, to
December 31,
1995 who have
been on
antidepressants

During
periods of
SSRI use
without use of
other drugs
associated with
upper GI
bleeding, 55
episodes of GI
bleeding
occurred. The
combined use
of an SSRI
with a
nonsteroidal
antiinflammatory
drug (NSAID)
or low-dose
aspirin
increased the
risk of an
upper GI
bleed. SSRIs
increase the
risk of upper
GI bleeding
with the
concurrent use
of an NSAID

These results can be taken
into consideration when
health care providers
prescribe SSRIs to children.
Caution should be taken if
the individual is already on
an NSAID or taking aspirin
so the risk of upper GI
bleeding can be avoided.
Nurses can provide teaching
to patients and families
regarding the risk of upper
GI bleeding with the
combination of an SSRI and
NSAID or aspirin.
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or low doseaspirin,
whereas the
risk of upper
GI bleeding
could not be
related to other
types of
antidepressants
.
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Articles

Manassis, K. (2005)
Paroxetine improves
social anxiety disorder
in children and
adolscnets. Evidence
Based Mental Health,
8(2), 43-43.

Purpose

Method

Study Design

Sample

Results (key
findings)

Nursing implications

To test if
paroxetine is
effective and
well tolerated in
children and
adolescents with
social anxiety
disorder

322 children and
adolescents
diagnosed with
social anxiety
disorder received
paroxetine 10
mg/day for the
first week and then
increased by 10
mg/week up to a
maximum dose of
50 mg. A placebo
pill was also used.
All participants
received age
appropriate
pamphlets on
social anxiety
disorder and selfhelp. Parents of
these children also
received
pamphlets. The
follow-up period
was 16 weeks.

Multicenter
randomized
double-blind,
placebocontrolled trial

322 children
and
adolescents
from the ages
of 8 to 17
years with
social anxiety
disorder
according to
the DSM-IV
criteria

Paroxetine
greatly
increased the
proportion of
responders at 16
weeks,
compared with
placebo. The
common
adverse effects
were insomnia,
decreased
appetite, and
vomiting. In the
children/adolesc
ents that
received
paroxetine five
had suicidal
ideation,
threatened
suicide, or selfharmed,
compared with
none in the
placebo group.
Paroxetine is
effective for

Paroxetine is an effective
SSRI that can be used to
treat anxiety disorders in
children and adolescents.
The findings suggest
very few suicidal
ideations and adverse
reactions which can be
reassuring to parents and
children.
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young people
and adolescents
with social
anxiety disorder
and produces
few serious
adverse
reactions.
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Articles

Purpose

Method

Lebowitz, E. R.,
Woolston, J.,
Bar‐Haim, Y.,
Calvocoressi, L.,
Dauser, C., Warnick,
E., ... & Leckman, J. F.
(2013). Family
accommodation in
pediatric anxiety
disorders. Depression
and anxiety, 30(1), 4754.

To test the utility
of the Family
Accommodation
Scale-Anxiety
(FAFSA) for
assessing family
accommodation
across childhood
anxiety disorders
and report on the
first study of
family
accommodation

Participants were
parents of anxious
children from two
anxiety disorder
specialty clinics
and a general
outpatient clinic.
Measures
included FAFSA,
diagnostic
interviews, and
measures of
anxiety and
depression.

Study Design
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Sample

Results (key
findings)

Nursing implications

75 parents of
anxious
children and
50 children
from an
anxiety
disorder
specialty
clinic and 25
children from
a general
outpatient
clinic.

Most parents
revealed family
distress and
modification of
family routines
resulting from
accommodation
and
consequences
from not
accommodating.
The FAFSA
showed good
consistency and
validity. The
FAFSA shows a
promising way
to assess for
accommodation
in childhood
anxiety
disorders.

The FAFSA can be used
in the health care setting
when families are
having a hard time
adjusting to their child’s
anxiety. This scale can
help families
accommodate so there
are fewer symptoms,
impairment, and poorer
treatment outcomes.
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Allgulander, C., Florea,
I., & Huusom, A. K. T.
(2006). Prevention of
relapse in generalized
anxiety disorder by
escitalopram
treatment. International
Journal of
Neuropsychopharmaco
logy, 9(5), 495.

To test the
efficacy and
tolerability of
escitalopram in
the prevention of
relapse in
generalized
anxiety disorder

Method

Study Design

All of the
Randomized
participants who
double-blind
were diagnosed
study
with a primary
diagnoses of
generalized
anxiety disorder
and a Hamilton
Anxiety score of
20 or more
received 12
weeks of a fixed
dose of
escitalopram (20
mg/day). Of the
491 participants,
375 responded
with a Hamilton
Anxiety score of
10 or less and
were randomized
to double-blind
treatment with 20
mg/day
escitalopram
(n=187) or
placebo (n=188).
Treatment was
ongoing for 24-76
44

Sample

Results (key
findings)

Nursing implications

491 patients
with a
diagnosis of
generalized
anxiety
disorder and a
Hamilton
Anxiety total
score of 20 or
more were
given 12
weeks of
escitalopram
20 mg/day.

The risk of
relapse was
higher for the
placebo group
than for the
escitalopram
treated group.
The proportion of
patients who
relapsed was
statistically
higher in the
placebo group
than in the
escitalopram
group.
Escitalopram was
tolerated and 20
mg/day of this
significantly
reduced the risk
of relapse in
patients with
generalized
anxiety disorder.

Relapse or the
recurrence of
symptoms after a
period of getting better
is a common problem
that patients face.
When this issue arises
regarding relapse in
generalized anxiety
disorders, health care
providers can prescribe
escitalopram as a way
to prevent relapse from
occurring. This can be
reassuring to patients
and families when they
feel as though their
symptoms are getting
worse or deteriorating.

weeks unless
however the
patient relapsed
or experienced
other adverse
reactions. Relapse
was defined as a
patient having a
score of 15 or
more in the
Hamilton Anxiety
scale.
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Articles

Purpose

Lovrin, M. (2009).
Treatment of Major
Depression in
Adolescents: Weighing
the Evidence of Risk
and Benefit in Light of
Black Box Warnings.
Journal of Child &
Adolescent Psychiatric
Nursing, 22(2), 63-68.

To inform
clinicians who
are concerned
with the FDA’s
black box
warning on the
increased risk of
suicidal ideation
and SSRIs in
adolescents with
major depressive
disorder.

Method

Relevant
literature from
2004 to 2006 as
well as a case
study based on
the author’s
clinical
experience.

Study Design

Review of the
literature on
the risks and
benefits of
SSRIs
regarding the
guidelines
issued by the
U.S. Food and
Drug
Administration
(FDA) and the
Medicines and
Healthcare
Products
Regulatory
Agency of the
United
Kingdom.
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Sample

Results (key
findings)

Relevant
There are risks
literature from and benefits in
2004-2006
SSRI usage that
clinicians need to
be aware of,
however they
remain as an
effective means
of treatment.
SSRIs as well as
patient and family
education
regarding side
effects should be
a part of the
treatment plan.

Nursing implications

After the FDA’s black
box warning on
antidepressants,
clinicians as well as
patients have raised
concern regarding
SSRIs. However,
despite the warning
they are still showing
to be effective in the
treatment of depressive
symptoms and anxiety
disorders. Nurses
should include
education on the side
effects of this class of
antidepressants to
patients and families.

Articles

Purpose

Method

Czaja, A. S., Valuck,
R. J., & Anderson, H.
D. (2013). Comparative
safety of selective
serotonin reuptake
inhibitors among
pediatric users with
respect to adverse
cardiac events.
Pharmacoepidemiology
And Drug Safety, 22(6),
607-614.

To perform a
comparative
safety study to
assess for the
risk of
ventricular
arrhythmia,
cardiac arrest, or
sudden death in
pediatric users
who are
prescribed
SSRIs.

Data taken from
1997 to 2009
from US claims
data of new
pediatric users
less than the age
of 18 taking
SSRIs were
identified.
Adverse cardiac
effects occurring
within 12 months
of the start of an
SSRI were
identified and
validated using
the International
Classification of
Disease. A cox
proportional
hazard analysis
was used to
estimate the risk
of each SSRI.

Study Design

Comparative
safety study
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Sample

Results (key
findings)

Nursing implications

113,714
pediatric users
of SSRIs less
than 18 years
of age were
included

Sertraline and
fluoxetine were
the most
commonly
prescribed SSRIs.
Forty events
occurred within
the 12 month
period of the start
of an SSRI. The
incidence rate of
cardiac adverse
effects was
highest for
escitalopram and
lowest for
fluoxetine.
Overall, the
incidence of
cardiac adverse
effects is low
among pediatric
SSRI users. The
risk of cardiac
adverse reactions
was higher for
citalopram and
escitalopram as

Health care providers
should prescribe SSRIs
with caution especially
when prescribing to the
pediatric population.
Adverse reactions are
always trying to be
avoided at all costs,
however there lies
some risk when
initiating an SSRI.
Nurses should educate
families and children
on the possible cardiac
adverse effects and
which medications
have a higher risk of
this than other
medications.

compared with
fluoxetine users.
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Articles

Purpose

Wolhfarth, T.D., van
Zwieten, B. J.,
Lekkerkerker, F. J.,
Gispen-de Wied, C. C.,
Ruis, J. R., Elferink, A.
J., & Storosum, J. G.
(2006). Antidepressants
use in children and
adolescents and the risk
of suicide. European
Neuropsychopharmaco
logy, 16(2), 79-83.

To examine
whether or not
all
antidepressants
are linked with a
risk of suicidal
behaviors.

Method

Study Design

All 22 pediatric
Random effect
short-term
meta-analysis
placebocontrolled trials
of SSRIs and
SNRIs were
identified and
examined for
events related to
suicidality. They
were categorized
into three
categories:
suicide, suicide
attempts, or
suicidal thoughts.
A random effect
meta-analysis was
used to gather the
information from
all the trials.
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Sample

Results (key
findings)

Nursing implications

22 pediatric
short-term
placebocontrolled
trials of SSRIs
and SNRIs

No completed
suicides were
reported.
However, from
each category
there was at least
one study with an
increased risk for
events related to
suicide. Caution
should be used in
the use of all
SSRIs and SNRIs
in the pediatric
population.

Nurses should forewarn
parents and children on
the increased risk of
suicide regarding
SSRIs. However,
clinicians and nurses
should not go to the
extent of frightening
parents to where they
do not want to proceed
with treatment. The
increased risk of it
should be mentioned
before starting any
child on an SSRI.

Articles

Isolan, L., Pheula, G.,
Salum, Jr, G. A.,
Oswald, S., Rohde, L.
A., & Manfro, G. G.
(2007). An open-label
trial of escitalopram in
children and
adolescents with social
anxiety
disorder. Journal of
child and adolescent
psychopharmacology,17
(6), 751-759.

Purpose

To evaluate the
efficacy and
safety of
escitalopram in
the treatment of
social anxiety
disorder in
children and
adolescents.

Method

Twenty
outpatients with a
primary
diagnoses of
social anxiety
disorder were
treated in a 12week open trial
with
escitalopram. The
changes were
looked upon from
the start of the
treatment to the
end using the
Clinical Global
ImpressionImprovement
scale. Other
measures used
included the
Clinical GlobalImpression scale,
the Social Phobia
and Anxiety
Inventory for
Children, the
Screen for Child

Study Design

Open-label
trial
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Sample

Results (key
findings)

Nursing implications

Twenty
outpatients
with a
primary
diagnoses of
social anxiety
disorder were
treated in a
12-week open
trial with
escitalopram.

On the Clinical
Global
ImpressionImprovement
sale, 13 out of
the 20 patients
had a score of 2
or less. Patients
showed
improvement in
symptoms and
quality of life
measures from
the start to week
12. These results
suggest that
escitalopram is
well tolerated
and
safe/effective for
pediatrics with
social anxiety
disorder.
However, future
studies are
warranted.

These results can
suggest that
escitalopram is indeed
well tolerated and safe
for pediatric users with
social anxiety
disorders. Clinicians
can safely prescribe
this SSRI to the
pediatric population
who are diagnosed with
social anxiety disorder.
When given options of
SSRIs, escitalopram
can safely be chosen.

and Anxiety
Related
Emotional
Disorders-Child
and Parent
Version, and The
Youth Quality of
Life InstrumentResearch Version.

51

Articles

Purpose

Method

Study Design

Sample

Results (key
findings)

Nursing implications

da Costa, C. Z. G., de
Morais, R. M. C. B.,
Zanetta, D. M. T.,
Turkiewicz, G., Neto,
F. L., Morikawa, M., ...
& Asbahr, F. R. (2013).
Comparison Among
Clomipramine,
Fluoxetine, and
Placebo for the
Treatment of Anxiety
Disorders in Children
and
Adolescents. Journal of
child and adolescent
psychopharmacology, 2
3(10), 687-692.

To test the
efficacy of
clomipramine,
fluoxetine and a
placebo and
compare their
action in children
and adolescents
with anxiety
disorders

The thirty
subjects were
submitted to a 12
week doubleblind,
randomized,
placebocontrolled trial of
clomipramine and
fluoxetine. The
measures used
included: the
Schedule for
Affective
Disorders and
Schizophrenia,
the
Multidimensional
Anxiety Scale for
Children, the
Children’s
Depression
Inventory, the
Clinical Global
Impression, and
the Children’s
Global
Assessment
Scale.

Double-blind,
randomized,
placebocontrolled trial

30 subjects
ages 7-17 who
were
diagnosed
with
generalized
anxiety
disorder
and/or
separation
anxiety
disorder
and/or social
phobia. N=9
for the
clomipramine
group, n=10
for the
fluoxetine
group, and
n=11 for the
placebo
group.

All groups
showed a
substantial
improvement
after 12 weeks of
treatment. There
were significant
improvement in
the fluoxetine and
placebo groups
regarding anxiety
severity and
impairment.
There were no
significant
differences
between
clomipramine and
placebo groups or
between
fluoxetine and
clomipramine
groups.

When prescribing
SSRIs it is vital to
know which ones have
been studied as more
effective and safer than
others. When
comparing
clomipramine and
fluoxetine health care
providers can
determine that they
both stand on the same
level of efficacy and
effectiveness.
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Articles

Purpose

Cooper, W. O.,
Callahan, S. T.,
Shintani, A., Fuchs, D.
C., Shelton, R. C.,
Dudley, J. A., ... &
Ray, W. A. (2014).
Antidepressants and
suicide attempts in
children. Pediatrics, 13
3(2), 204-210.

To compare the
risk of medically
treated suicide
attempts among
new users of
sertraline,
paroxetine,
citalopram,
escitalopram, and
venlafaxine to the
risk of new users
of fluoxetine.

Method

Study Design

A retrospective
Retrospective
cohort study
cohort study
included 36, 825
first time users of
one of the
antidepressant
medications
listed. The sample
included children
aged 6-18 years
of age enrolled in
Tennessee
Medicaid
between 1996 and
2006. Medically
treated suicide
attempts were
identified from
Medicaid files
and confirmed
with medical
record review.
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Sample

Results (key
findings)

Nursing implications

36,842
children aged
6-18 years
enrolled in
Tennessee
Medicaid
between
1995 and
2006

Confirmed through
the medical record
review, 419
members of the
study had a
medically treated
suicide attempt
with the intentions
or explicit attempt
to die. Of these
419 cohort
members, 4
actually completed
suicide. There was
not a significant
difference among
the current users of
SSRIs and SNRIs
compared with the
users of fluoxetine.
However, users of
multiple
antidepressants
had increased risk
for suicide
attempt. There was
no evidence that
the risk of suicide
attempts differed
for commonly

It is important to raise
awareness to children,
families, and health
care providers of the
increased risk of
suicide and suicide
attempts in children
prescribed SSRIs. It is
a huge concern that still
comes up as a topic of
discussion when
children are treated
with SSRIs for their
anxiety. Nurses should
provide the more
current and reliable
education regarding the
increased risk of
suicide/suicide attempts
to families.

prescribed SSRIs
and SNRIs.
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Articles

Purpose

Method

Study Design

Sample

Results (key
findings)

Nursing implications

Piacentini, J., Bennett,
S., Compton, S. N.,
Kendall, P. C.,
Birmaher, B., Albano,
A. M., ... & Walkup, J.
(2014). 24-and 36week outcomes for the
Child/Adolescent
Anxiety Multimodal
Study
(CAMS). Journal of the
American Academy of
Child & Adolescent
Psychiatry, 53(3), 297310.

To report active
treatment group
differences on
response and
remission rates
and changes in
anxiety severity at
weeks 24 and 36
for the
Child/Adolescent
Anxiety
Multimodal Study
(CAMS).

488 youths aged
7-17 years
diagnosed with
separation,
generalized, or
social anxiety
disorder were
randomized to 12
weeks of CBT,
sertraline, the
combination of
CBT and
sertraline, or pill
placebo. 412
youths were
randomly
assigned to CBT,
sertraline, and
combination. 76
youths were
randomized to the
pill placebo.
Participants
attend 6 monthly
booster sessions.
Efficacy of CBT,
sertraline, and the
combination were
assessed at 24 and
36 weeks. Youths
in the placebo

Randomized
controlled
multi-site
comparative
treatment trial

488 youths
aged 7-17
years who
meet the
criteria on the
DSM-IV-TR
for social
phobia,
separation
anxiety,
and/or
generalized
anxiety
disorder, and
their parents

80% of the
participants
showed a positive
response at weeks
24 and 36. The
combination of
sertraline and
CBT upheld an
advantage over
CBT and
sertraline alone.
Compared to the
combination of
CBT and
sertraline and
CBT alone, youth
in sertraline
obtained more
concomitant
psychosocial
treatments,
whereas the youth
in sertraline and
CBT obtained
more concomitant
treatment. The
combination of
CBT and
sertraline had an
advantage over
CBT and

Nurses and clinicians
should encourage
patients and families to
combine psychosocial
treatment with
medication treatment
since the CAMS
showed the
effectiveness of the
combination than CBT
and sertraline on its
own. This can
potentially leave
parents less tense about
having their child on
medication treatment
alone. This study can
also lead towards new
research on other
psychosocial treatment
that can be used with
medications.

55

group who were
nonresponsive
after week 12
were offered
active CAMS
treatment. Blind
independent
evaluators
assessed anxiety
severity,
functioning, and
treatment
response.

sertraline alone.
CBT and
sertraline
remained
indistinguishable.
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Articles

Purpose

Method

Schneeweiss, S.,
Patrick, A. R.,
Solomon, D. H.,
Dormuth, C. R., Miller,
M., Mehta, J., ... &
Wang, P. S. (2010).
Comparative safety of
antidepressant agents
for children and
adolescents regarding
suicidal
acts. Pediatrics, peds2009.

To assess the risk
of suicide
attempts and
suicide after the
start of an
antidepressant
medication use
by children and
adolescents.

A 9-year cohort
study was
conducted by
using population
wide data from
British Columbia.
Adolescents and
children from the
ages of 10-18
were identified as
a new user of an
antidepressant
and with a
recorded
diagnosis of
depression. Study
outcomes
included
hospitalizations
caused by
intentional selfharm and suicide
death.

Study Design

9- year cohort
study
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Sample

Results (key
findings)

Nursing implications

20,906
children/adoles
cents aged 1018 years

80% of the
20,906
children/adolesc
ents had no
previous history
of antidepressant
use. During the
first year of
observation, 266
attempted
suicide and 3
completed
suicide. There
were no
significant
differences in
rate ratios
comparing
fluoxetine and
citalopram,
fluvoxamine,
paroxetine, and
sertraline. The
findings support
FDA’s issue of
the black box
warning on all
antidepressants
regarding

The black box warning
on antidepressants is an
important concern to
bring up to families and
children. Even though
there is a slight
increased risk of
suicide, clinicians and
nurses should not
portray the warning as
a means to not start on
an antidepressant.

increased risk of
suicide in
children and
adolescents
beginning
antidepressants.

58

Articles

Rynn, M. A., Walkup,
J. T., Compton, S. N.,
Sakolsky, D. J.,
Sherrill, J. T., Shen, S.,
... & Birmaher, B.
(2015).Child/Adolesce
nt Anxiety Multimodal
Study: Evaluating
Safety. Journal of the
American Academy of
Child & Adolescent
Psychiatry, 54(3), 180190.

Purpose

To evaluate the
frequency of
adverse events
across 4
treatments in the
CAMS and to
compare the
frequency of
adverse events
between children
and adolescents.

Method

Study Design

Sample

Results (key
findings)

Nursing implications

Participants
included children
and adolescents
from the ages of
7-17 with one or
more of the
following
disorders:
separation anxiety
disorder,
generalized
anxiety disorder,
or social phobia
based on the
criteria of the
DSM-IV criteria.
The participants
were grouped into
cognitivebehavioral
therapy (n=139),
sertraline
(n=133), a
combination of
them both
(n=140), or pill
placebo (n=76).
Data on the
adverse reactions

Randomized
controlled
multi-site
comparative
treatment trial

488 children
and
adolescents
aged 7-17
years who
were
diagnosed with
one of the
following
disorders:
separation
anxiety
disorder,
generalized
anxiety
disorder, or
social phobia
based on the
criteria of the
DSM-IV
criteria were
included in the
study.

There were no
differences
between the
sertraline versus
placebo for
physical and
psychiatric
adverse reactions
or any individual
physical or
psychiatric
adverse events.
The total
physical adverse
events were
higher in the
sertraline alone
treatment when
compared to
CBT and the
combination.
The participants
who received
sertraline alone
reported higher
rates of physical
adverse reactions
when compared
to the

It is important to
evaluate safety on
SSRIs especially when
prescribing them to the
pediatric population. It
is vital to have nurses
provide education to
families and children
especially under the
age of 12 of possible
physical adverse
reactions. Families and
children should be told
what to expect from the
medications and all the
physical adverse events
that can arise. This can
potentially ease up
tension between
parents.
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were drawn from
a standardized
inquiry method
and a self-report
physical
symptoms
checklist.

combination and
CBT. Physical
adverse events
were higher in
children less
than or equal to
12 years of age.
The results
support the
safety and
tolerability of
SSRIs for
treatment of
anxiety
disorders.
Additional
monitoring for
physical adverse
reactions is
recommend for
children 12 years
or younger.
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Articles

Smith, E. G. (2009).
Association between
antidepressant half-life
and the risk of suicidal
ideation or behavior
among children and
adolescents:
confirmatory analysis
and research
implications. Journal
of affective
disorders, 114(1), 143148.

Purpose

To determine if
from a recent
meta-analysis of
pediatric
antidepressants
trials if the
multiple-dosing
medication halflife is associated
with the risk of
suicidal ideation
or behavior.

Method

Study Design

Sample

Results (key
findings)

Nursing implications

Based on the
FDA’s initial and
published
versions of their
pediatric
antidepressant
meta-analysis,
risks (ideation,
attempt, or
preparation) for
suicidal behavior
for seven
antidepressants
were obtained.
The risk of
suicidal behavior
and
antidepressant
half-life was
examined using a
nonparametric
test.

Confirmatory
analysis/Nonpar
ametric test,
Spearman’s rho

Relative risks
for suicidal
ideation,
attempt, or
preparation
for seven
antidepressant
s were
obtained from
both the
FDA's initial
and published
versions of
their pediatric
antidepressant
meta-analysis

A significant
correlation was
observed for the
initial analysis.
With fluoxetine
the correlation
was strong to a
change in
suicidality
ranking which
has the longest
half-life among
antidepressants.
This occurred
when results
from the
Treatment of
Adolescent
Depression
Study were
included in the
meta-analysis.
The risk for
suicidal ideation
or behavior in
short-term
antidepressants
appears to at
least partly be

Clinicians should
consider the half-life of
antidepressants when
prescribing them to
children and
adolescents. This is
important since the
study suggests an
association with shortterm antidepressants
and risk of suicidal
ideation. Nurses can
inform
children/adolescents
and families about
antidepressants half-life
and the relative risk of
suicidal ideation.
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associated with
antidepressant
half-life.
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Articles

Fergusson, D.,
Doucette, S., Glass, K.
C., Shapiro, S., Healy,
D., Hebert, P., &
Hutton, B. (2005).
Association between
suicide attempts and
selective serotonin
reuptake inhibitors:
systematic review of
randomised controlled
trials.Bmj, 330(7488),
396.

Purpose

To determine
whether there is
an association
between use of
SSRIs and
suicide attempts

Method

Studies were
randomized in
controlled trials
comparing an
SSRI with either
a placebo or nonSSRI. The study
included clinical
trials that
assessed any
clinical condition.
Researchers
excluded
abstracts,
crossover trials,
and all trials
whose follow up
period was less
than a week.

Study Design

Systematic
review of
controlled
trials
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Sample

Results (key
findings)

Nursing implications

87,650
patients
included in
seven hundred
and two trials

A significant
increase in the
odds of suicide
attempts were
observed for
patients
prescribed SSRIs
compared to the
placebo. An
increase in the
odds of suicide
attempts was also
noted in
comparing SSRIs
with therapeutic
interventions
other than
tricyclic
antidepressants.
There was not a
difference in the
odds ratio of
suicide attempts
in the pooled
analysis of SSRIs
versus tricyclic
antidepressants.

Because of the
increased risk of
suicidal ideation in
patients prescribed
SSRIs, educating
patients and families
about it is very
important. Nurses
should be up-to-date on
the latest statistics
regarding suicidal
ideation and the
association between
antidepressants.
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